Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-09-20
Based on 532 first isolates · SURG · Skin / wound infection · 2025-09-21 → 2026-09-20
Surgery
Per-organism detail: SURG wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 54 % (50 %–58 %)
Best two-drug combination: vancomycin + meropenem covers 99 % (97 %–99 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (16 %), Escherichia coli (11 %), Proteus mirabilis (10 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
54 %
65 %
n = 40
meropenem MEM
trend · Pseudomonas aeruginosa reserve
45 %
33 %
n = 40
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
41 %
23 %
n = 40
41 %
33 %
n = 40
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
41 %
53 %
n = 40
ceftriaxone CRO
trend · Escherichia coli
28 %
23 %
n = 40
26 %
20 %
n = 40
25 %
25 %
n = 40
14 %
10 %
n = 40
mecillinam MEC
not for this site
0 %
0 %
n = 40
trimethoprim TMP
not for this site
0 %
0 %
n = 40
nitrofurantoin NIT
not for this site
0 %
0 %
n = 40

Most likely organisms for this profile

Staphylococcus aureus
42 %
Pseudomonas aeruginosa
16 %
Enterococcus faecalis
12 %
Escherichia coli
11 %
Proteus mirabilis
10 %
Citrobacter freundii
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.